Innate Pharma (IPHA) Interest Expenses (2019 - 2025)
Innate Pharma's (IPHA) quarterly Interest Expenses came in at -$3.6 million in Q4 2025, up 14.5% YoY from -$3.2 million in Q4 2024, and down 14.46% on a QoQ basis from -$3.2 million in Q2 2025.
Innate Pharma (IPHA) Interest Expenses (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Interest Expenses data on file, last reported at -$3.6 million in Q4 2025.
- Quarterly Interest Expenses rose 14.5% year-over-year to -$3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.3 million (down 39.79% YoY) and the FY2025 annual result came in at $3.6 million, down 14.5% from the prior year.
- Interest Expenses declined to -$3.6 million in Q4 2025, from -$3.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of -$5428.7 in Q4 2022 to a low of -$4.6 million in Q4 2021.
- A 5-year average of -$2.6 million and a median of -$2.7 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 99.88% — and 2023, when it sank 36268.5%.
- Tracing IPHA's Interest Expenses over 5 years: stood at -$4.6 million in 2021, then jumped by 99.88% to -$5428.7 in 2022, then slumped by 36268.5% to -$2.0 million in 2023, then tumbled by 115.14% to -$4.2 million in 2024, then rose by 14.5% to -$3.6 million in 2025.
- The last three Interest Expenses figures came in at -$3.6 million (Q4 2025), -$3.2 million (Q2 2025), and -$4.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 93.62 Mn |
| 10 | Innate Pharma | 205.61 Mn | 205.61 Mn | - | -3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.63 Mn |
| Dec 31, 2025 | -3.63 Mn |
| Jun 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -3.17 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Dec 31, 2023 | -1.97 Mn |
| Dec 31, 2023 | -1.97 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Dec 31, 2022 | -5,428.74 |
| Dec 31, 2022 | -5,428.74 |
| Dec 31, 2021 | -4.57 Mn |
| Dec 31, 2021 | -4.57 Mn |
| Dec 31, 2020 | -8.06 Mn |
| Dec 31, 2020 | -8.06 Mn |
| Dec 31, 2019 | -5.51 Mn |
| Dec 31, 2019 | -5.51 Mn |